Aurinia Pharmaceuticals LUPKYNIS Approved for LN in Adults
Aurinia Pharmaceuticals (AUPH) has been granted a U.S. FDA approval of its product LUPKYNIS™ (voclosporin) in combination with a background immunosuppressive therapy regimen to treat adult patients with active lupus nephritis (LN).
LN is a serious progression of systemic lupus erythematosus (SLE) - a chronic, complex and . . .